\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Clinical Characteristics and Histopathological Findings in Renal Parenchymal Disease Patients: our Single Centre Experience from Northern Plains of India},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2015-01-15 (revised: 15 January 2015)}
\def\TheID{\makeatother }
\def\TheDate{2015-01-15}
\title{Clinical Characteristics and Histopathological Findings in Renal Parenchymal Disease Patients: our Single Centre Experience from Northern Plains of India}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Rahul  Mannan}

             \author[2]{Pramela Anthony  Singh}

             \author[3]{Vatsala  Misra}

             \author[4]{Mamta  Singh}

             \author[5]{Sneh Lata  Tewarson}

             \affil[1]{  Sri Guru Ram Das Institute of Medical Sciences and Research, Vallah, Amritsar (Punjab), India}

\renewcommand\Authands{ and }

\date{\small \em Received: 7 December 2014 Accepted: 2 January 2015 Published: 15 January 2015}

\maketitle


\begin{abstract}
        


Introduction: For renal diseases, renal biopsy is considered gold standard to reach a diagnosis. The present study was undertaken to understand and analyze clinical symptoms, lab findings and final histological diagnosis for clinico-pathological correlation.Material and Methods: The present prospective study comprised of 127 patients who underwent per-cutaneous renal biopsies over a period of three years. Before undertaking renal biopsies the clinical findings along with biochemical and urinary investigations were done.

\end{abstract}


\keywords{ANCA, clinico-pathological, end stage renal disease, glomerulonephritis, renal diseases.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
idney diseases manifest in many ways. A patient may be asymptomatic or may be suffering with a life threatening emergency. Apart from the clinical history, ancillary investigations, including urine examination and radiological investigations; renal biopsy is considered gold standard in reaching a diagnosis in many conditions especially in cases of acute renal failure (ARF). Renal biopsy is also the most definitive method of differentiating acute from chronic kidney disease and various renal/tubule-interstitial disorders. The underlying cause of most glomerular diseases remains an enigma. Infectious agents, autoimmunity, drugs, inherited disorders and environmental agents have been implicated as the cause of certain glomerular diseases. \hyperref[b0]{1} The present study was undertaken over a period of three years in a single tertiary care center in the northern part of India so as to take a glimpse of the pattern of disease in an area which is highly resource challenged. A comparison was also drawn with areas in and around Indian subcontinent. A major part of the present study was to understand and analyze clinical symptoms and findings with laboratory investigations and final histopathological diagnosis (clinicopathological correlation). The biopsies were also tabulated according to auto-immune serological panel as well. 
\section[{II.}]{II.} 
\section[{Materials and Methods}]{Materials and Methods}\par
The present prospective study comprised of 127 patients who underwent percutaneous renal biopsies over a period of three years (2005-2007)  pertaining to renal parenchymal disease. The study was\par
The present prospective study comprised of 127 patients who underwent per-cutaneous renal biopsies over a period of three years. Before undertaking renal biopsies the clinical findings along with biochemical and urinary investigations were done.\par
Specimens were subjected to light microscopic studies (with Hematoxylin and Eosin, periodic Schiff, Massons Trichrome and periodic methenamine silver). Autoimmune panel was employed in 79 cases. All the findings were noted and tabulated.\par
Results Most of the patients who underwent renal biopsy were of nephrotic range proteinuria (40.15\%). End stage renal disease (ESRD) was the most common glomerulopathy. Lupus nephritis was the most common secondary glomerulopathy recorded. 12.5 \% cases were also seropositive for anti-neutrophilic cytoplasmic antibody (ANCA). Of the clinical symptoms oliguria/anuria with anasarca were the commonest recorded followed by fever, loss of appetite and malaise Conclusion The present study which was truly a clinicopathological study not only adds on to the available Indian literature about spectrum of glomerulopathies in a region of poor human developmental indices but also stresses on the very innocuous sounding symptoms of urinary disturbance and anasarca presenting with fever and weight loss as important pointers towards renal diseases. The finding of ESRD as the most common glomerulopahy in the region done in conjunction with department of pathology and nephrology MLN medical college with SRN hospital, Allahabad, Uttar Pradesh (India). Most of the patients included in the biopsy were of adult age group with very few pediatric samples. The study was conducted after obtaining approval from the ethical committee of the institute. In all the cases informed consent was obtained.\par
Four per-cutaneous core (specimen) biopsies were retrieved after ultra-sonographic localization of the kidneys in each individual case. The patients complain and complications post procedures were noted.\par
Specimens were subjected to light microscopic studies (with Hematoxylin and Eosin, periodic Schiff, Massons Trichrome and periodic methenamine silver). Due to economic constraints immunofluoresence studies were done wherever possible. Biopsy samples were considered satisfactory for diagnosis if they contained five or more glomeruli. Biopsies were categorized as inadequate for diagnosis if glomeruli were less than 5. A total of 3 pathologists reviewed and reported the histopathological slides over this period to limit the interpersonal bias. The final diagnoses were then tabulated to ascertain the spectrum of glomerular diseases.\par
The indications for performing the biopsies were nephrotic syndrome, nephritic syndrome, acute and chronic renal failure of known/unknown etiology, persistent or recurrent asymptomatic hematuria or proteinuria. The biopsies were tabulated according to age, sex, clinical complaints and findings and lab investigation findings (notably urine examination and biochemical examination). The final histopathological diagnoses were then extrapolated on the clinical presentation and laboratory findings for clinicopathological deductions.\par
Autoimmune panel was employed in 79 cases which included-complement levels (C3/C4), anti nuclear antibody (ANA), double stranded DNA (dsDNA), perinuclear anti neutrophilic cytoplasmic antibody (P-ANCA), cytoplasmic anti neutrophilic cytoplasmic antibody (C-ANCA), anti glomerular basement memberane (Anti-GBM) and cryoglobulins detection. 
\section[{III.}]{III.} 
\section[{Results}]{Results} 
\section[{a) Glomeruolopathy Spectrum}]{a) Glomeruolopathy Spectrum}\par
A total of 127 renal biopsies were performed at our centre during the study of which 7 were considered inadequate. There were 86 (67.71\%) males and 41 (32.28\%) females with male to female ratio being 2:1. The male predominance was virtually present in every lesion except for those seen in lupus nephritis, renal cortical necrosis and in a single recorded case of focal global glomerulosclerosis. The average age of the patients who underwent the procedure was 34 years. (Table \hyperref[tab_0]{-1} The overall complication rate in this study was 2.0\%. Local pain at the biopsy site was noted in 1.5\% with gross/ microscopic hematuria was noted in 0.5\% patients.\par
Most of the cases who underwent biopsy were of nephrotic range proteinuria (51 patients; 40.15 \%) followed by nephritic syndrome (30 patients; 23.62 \%) and sub-nephrotic range proteinuria (21 patients; 16.53\%). A few cases also underwent renal biopsy having presenting complains of renal failure of uncertain etiology (15 patients; 11.81\%) and asymptomatic hematuria (10 patients; 7.87\%). (Table \hyperref[tab_1]{-2} Secondary glomerulopathy was found in 19 cases (15.0\%); most common pathology was lupus nephritis (4.96\%) followed by diabetic nephropathy (4.34\%) and amyloid nephropathy (2.48\%).\par
Serological studies concluded that 15 cases (12.5 \%) were serologically P-ANCA, C-ANCA or both positive and were categorized as ANCA positive biopsies. P-ANCA positivity accounted for the maximum number of ANCA cases (80.00\%) whereas C-ANCA positivity was seen in 13.33\% of all ANCA cases. Rest of the cases (20.00\%) on serology were showed positivity for both C-ANCA and P-ANCA.\par
Of all the serologically ANCA positive cases; the maximum number of cases were of end stage renal disease (ESRD) (26.66 \%). Focal and segmental mesangial proliferative and crescentic glomerulonephritis without fibrinoid necrosis were the next most common category (20.00 \%) followed by necrotizing crescentic glomerulonephritis (13.33 \%). Necrotizing glomerulonephritis, focal proliferative and membranous with foci of fibrinoid necrosis were the least commonly seen (6.66 \%).(Table  {\ref -}3) Study also recorded the various biochemical and urinary findings in all the cases at the time of the biopsy which are discussed in details according to individual glomerulopathies under Table  {\ref -}    
\section[{Discussion}]{Discussion}\par
In the present study, nephrotic range proteinuria, was detected in majority of patients who underwent renal biopsy at our centre. This is comparable to the study by Balakrishnan et al \hyperref[b1]{2} and Narasimhan et al \hyperref[b2]{3} who also reported nephrotic syndrome (proteinuria >3.5 g/24 hr) as the major clinical presentation in Indian adults undergoing renal biopsy.\par
The predominant primary glomerular pathology in our study was ESRD followed by MGN and MPGN. The present study was conducted in a tertiary care hospital in North Indian state of eastern Uttar Pradesh and hence represents data analysis from this region. This is in contrast to other Indian studies which have recorded MEGN as the commonest injury pattern followed by MGN. \hyperref[b3]{4,}\hyperref[b4]{5} In a few studies from north India MCD is the commonest recorded injury pattern. \hyperref[b5]{6} Asian studies done in Saudi Arabia and China have reported MPGN as the most common glomerulaopathy followed by FSGS. \hyperref[b6]{7,}\hyperref[b7]{8,}\hyperref[b8]{9} The spectrum of glomerular disease is a little different in European and American context where Ig A nephropathy is the most common patern of glomerular injury. \hyperref[b4]{5} Also it was noted in the present study that ESRD was not only the most common injury pattern noted overall but also in the cases of systemic vasculitis.\par
Thus in contrast to the documented finding of most common histological findings of cresenteric type glomerulonephritis in cases of systemic vasculitis \hyperref[b9]{10} and MEGN in non systemic vasculitis cases by various researchers, diffuse global glomerulosclerosis/ ESRD was the most common histological finding in our group. This in turn points towards a poor socio-economic indicators in patients from in and around north gangectic plains of Allahabad region and reflects delayed presentation and patient ignorance about and complications of renal diseases as a great challenge to nephrologists practising in this region. This is in turn the larger scenario noted in many developing countries of Asia and Africa which are highly resource challenged. The probable reasons for having a different spectrum of renal diseases in different regions of same country and internationally is attributed to the multiple factors such as environmental (infectious as well as noninfectious), human developmental indices, facilities and access to health facilities, degree of health education, presentation of patient in physician OPD to final diagnosis). \hyperref[b10]{11} The second part of study which studied in details the clinical features with renal diseases overall and with specific glomerulopathies also detail presence of urinary disturbances ( anuria/oliguria) and anasarca if presenting with fever and weight loss as the lower most common denominators in screening out all patients who would eventually be diagnosed to be suffering from glomerulopathies.\par
This becomes important in educating patients as well as physicians as pyuria and hematuria are often thought as red -herrings by both as the features associated with glomerulopathies. But as noted in the study conducted this is often not the case in these patients as despite high urea and creatinine levels and discordance in various other urinary parameters, patients with glomerular diseases present late when only possible therapy is renal replacement either dialysis or renal transpalnation.\par
Similary very exuberatnt hematuria was noted in renal cortical necrosis and diffuse proliferative glomerulonephritis. Pyuria was seen in cases of secondary glomerulonephritis especially associated with diabetic nephropathy and ESRD. Often in these cases the patients were in higher grade of renal failure with features consistent with those of uremia. In the present study the range of increased urea levels was from 80-210.8 mg/dl with higher values recorded in ESRD. Very high creatinine values were seen in two ends of spectrum of renal failure with an average creatinine value of 7.10 in cases of acute renal failure associated with cresentic glomerulonephritis and chronic renal failure associated with ESRD. These findings are also corroborated with work done previously by various researches.  {\ref 12,} {\ref 13,} {\ref 14} prompt both the practising physicians and the pathologist in this region to be ever vigilant against a possibility of glomerulopathy in patients attending outpatients so that early action can be initiated to preserve kidney function and to avoid renal replacement therapies which add on to the morbidity and economic burden to the patients. In this regard work by government and non government organization to educate masses in this region can also go a long way to prevent kidney failure and reduce the prevalence of ESRD. Comparing the biochemical and urinary findings with other studies, it was found that nephrotic range proteinuria of 4+ was seen in minimal change disease only with 3+ proteinuria noted in FSGS, ESRD and MeM glomerulonephritis. The proteinuria in rest of the glomerulonephritis was sub-nephritic to minimal.\par
[Table \hyperref[tab_2]{-3]} The present study which was truly a clinicopathological study not only adds on to the available Indian literature about spectrum of glomerulopathies in a region of poor human developmental indices but also stresses on the very innocuous sounding symptoms of urinary disturabce and anasarca presenting with fever and weight loss as important pointers towards renal diseases. The finding of ESRD as the most common glomerulopahy in the region under investigation should 13. Reichert LJM, Koene RAP, Wetzel JFM. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998, 31: 1-11. 14. Schena FP. A retrospective analysis of the natural history of primary Ig A nephropathy worldwide. Am j Med 1990, 89: 209-215.  
\section[{Legends to Figures}]{Legends to Figures}\begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-2.png}
\caption{\label{fig_2}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{12222233333}\includegraphics[]{image-3.png}
\caption{\label{fig_3}Figure 1 :Figure 2 :Figure 2 AFigure 2 BFigure 2 CFigure 2 DFigure 3 :Figure 3 AFigure 3 BFigure 3 CFigure 3 D}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.01644100580270793\textwidth}P{0.14714700193423597\textwidth}P{0.23099613152804643\textwidth}P{0.036170212765957444\textwidth}P{0.091247582205029\textwidth}P{0.08138297872340425\textwidth}P{0.045212765957446804\textwidth}P{0.031237911025145067\textwidth}P{0.08631528046421663\textwidth}P{0.08384912959381044\textwidth}}
Year 2015\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
( D D D D )\tabcellsep SN\tabcellsep GLOMERULONEPHRITIS\tabcellsep TOTAL\tabcellsep \% OF ALL\tabcellsep \% OF\tabcellsep \multicolumn{3}{l}{MALE FEMALE NO.OF}\tabcellsep AVG.\\
\tabcellsep \tabcellsep (GLN.)\tabcellsep \tabcellsep LESIONS\tabcellsep GLN.\tabcellsep \tabcellsep \tabcellsep GLO/\tabcellsep AGE\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep BIOPSY\\
\tabcellsep 1\tabcellsep End Stage Renal Disease\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep (ESRD)\tabcellsep 21\tabcellsep 13.04\tabcellsep 16.53\tabcellsep 15\tabcellsep 06\tabcellsep 12.81\tabcellsep 37.91\\
\tabcellsep 2\tabcellsep Membranous\tabcellsep 16\tabcellsep 09.93\tabcellsep 12.59\tabcellsep 12\tabcellsep 04\tabcellsep 08.50\tabcellsep 34.75\\
\tabcellsep 3\tabcellsep Mesangial Proliferative\tabcellsep 11\tabcellsep 06.83\tabcellsep 08.66\tabcellsep 07\tabcellsep 04\tabcellsep 12.08\tabcellsep 31.77\\
\tabcellsep 4\tabcellsep Diffuse Proliferative\tabcellsep 10\tabcellsep 06.21\tabcellsep 07.87\tabcellsep 08\tabcellsep 02\tabcellsep 13.22\tabcellsep 36.66\\
\tabcellsep 5\tabcellsep Focal Segmental/ Proliferative\tabcellsep 10\tabcellsep 06.21\tabcellsep 07.87\tabcellsep 07\tabcellsep 03\tabcellsep 15.40\tabcellsep 49.33\\
\tabcellsep 6\tabcellsep Membrano Proliferative\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep (MPGN)\tabcellsep 08\tabcellsep 04.96\tabcellsep 06.29\tabcellsep 04\tabcellsep 04\tabcellsep 13.87\tabcellsep 27.64\\
\tabcellsep 7\tabcellsep Systemic Lupus\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep Erythematosus (SLE)\tabcellsep 08\tabcellsep 04.96\tabcellsep 06.29\tabcellsep 01\tabcellsep 07\tabcellsep 14.42\tabcellsep 33.56\\
\tabcellsep 8\tabcellsep Diabetic Nephropathy\tabcellsep 07\tabcellsep 04.34\tabcellsep 05.51\tabcellsep 04\tabcellsep 03\tabcellsep 16.57\tabcellsep 48.20\\
\tabcellsep 9\tabcellsep Focal Segmental\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep Glomerulosclerosis (FSGS)\tabcellsep 07\tabcellsep 04.34\tabcellsep 05.51\tabcellsep 06\tabcellsep 01\tabcellsep 09.57\tabcellsep 17.57\\
\tabcellsep \multicolumn{2}{l}{10 Inadequate}\tabcellsep 07\tabcellsep 04.34\tabcellsep 05.51\tabcellsep 06\tabcellsep 01\tabcellsep 00.00\tabcellsep 34.66\\
\tabcellsep \multicolumn{2}{l}{11 Crescentic}\tabcellsep 05\tabcellsep 03.10\tabcellsep 03.93\tabcellsep 05\tabcellsep 00\tabcellsep 05.80\tabcellsep 27.00\\
\tabcellsep \multicolumn{2}{l}{12 Minimal Change Disease}\tabcellsep 05\tabcellsep 03.10\tabcellsep 03.93\tabcellsep 03\tabcellsep 02\tabcellsep 08.40\tabcellsep 14.40\\
\tabcellsep \multicolumn{2}{l}{13 Amyloid Nephropathy}\tabcellsep 04\tabcellsep 02.48\tabcellsep 03.14\tabcellsep 04\tabcellsep 00\tabcellsep 18.75\tabcellsep 33.75\\
\tabcellsep \multicolumn{2}{l}{14 Normal}\tabcellsep 03\tabcellsep 01.86\tabcellsep 02.36\tabcellsep 03\tabcellsep 00\tabcellsep 03.66\tabcellsep 37.00\\
\tabcellsep \multicolumn{2}{l}{15 Renal Cortical Necrosis}\tabcellsep 02\tabcellsep 01.24\tabcellsep 01.57\tabcellsep 00\tabcellsep 02\tabcellsep 11.50\tabcellsep 37.00\\
\tabcellsep \multicolumn{2}{l}{16 Benign Nephrosclerosis}\tabcellsep 01\tabcellsep 00.62\tabcellsep 00.78\tabcellsep 01\tabcellsep 00\tabcellsep 10.00\tabcellsep 60.00\\
\tabcellsep \multicolumn{2}{l}{17 Focal Necrotizing}\tabcellsep 01\tabcellsep 00.62\tabcellsep 00.78\tabcellsep 01\tabcellsep 00\tabcellsep 04.00\tabcellsep 60.00\\
\tabcellsep \multicolumn{2}{l}{18 Focal Global}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep Glomerulosclerosis\tabcellsep 01\tabcellsep 00.62\tabcellsep 00.78\tabcellsep 00\tabcellsep 01\tabcellsep 40.00\tabcellsep 07.00\\
\tabcellsep \tabcellsep TOTAL\tabcellsep 127\tabcellsep 78.39\tabcellsep \tabcellsep 87\tabcellsep 40\tabcellsep 12.14\tabcellsep 34.90\end{longtable} \par
  {\small\itshape [Note: CVolume XV Issue 1 Version I]} 
\caption{\label{tab_0}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2} \par 
\begin{longtable}{P{0.45427974947807925\textwidth}P{0.005323590814196242\textwidth}P{0.005323590814196242\textwidth}P{0.04258872651356994\textwidth}P{0.2253653444676409\textwidth}P{0.012421711899791231\textwidth}P{0.02661795407098121\textwidth}P{0.07807933194154489\textwidth}}
\tabcellsep \tabcellsep \tabcellsep SN\tabcellsep \multicolumn{2}{l}{Indication}\tabcellsep Total\tabcellsep Incidence\\
\tabcellsep \tabcellsep \tabcellsep 1\tabcellsep \multicolumn{2}{l}{Nephrotic Syndrome}\tabcellsep 51\tabcellsep 40.15\%\\
\tabcellsep \tabcellsep \tabcellsep 2\tabcellsep \multicolumn{2}{l}{Nephritic Syndrome}\tabcellsep 30\tabcellsep 23.62\%\\
\tabcellsep \tabcellsep \tabcellsep 3\tabcellsep \multicolumn{2}{l}{Sub-Nephrotic Proteinuria}\tabcellsep 21\tabcellsep 16.53\%\\
\tabcellsep \tabcellsep \tabcellsep 4\tabcellsep \multicolumn{2}{l}{Renal Failure of uncertain}\tabcellsep 15\tabcellsep 11.81\%\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{etiology}\\
\tabcellsep \tabcellsep \tabcellsep 4\tabcellsep \multicolumn{2}{l}{Asymptomatic hematuria}\tabcellsep 10\tabcellsep 07.87\%\\
Of\tabcellsep all\tabcellsep the\tabcellsep \multicolumn{2}{l}{glomerulopathies,}\tabcellsep primary\\
\multicolumn{6}{l}{glomerulonephropathy was observed in 108 patients}\\
\multicolumn{6}{l}{(85.0\%) with end stage renal disease (ESRD) was the}\\
\multicolumn{6}{l}{commonest recorded lesion followed by membranous}\\
\multicolumn{6}{l}{glomerulonephritis (MGN) and Mesangioproliferative}\\
\multicolumn{6}{l}{(MeGN) glomerulonephritis (MPGN) respectively.}\\
(Table-1)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_1}Table 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{3} \par 
\begin{longtable}{P{0.1286697247706422\textwidth}P{0.02014525993883792\textwidth}P{0.011047400611620795\textwidth}P{0.02209480122324159\textwidth}P{0.08058103975535168\textwidth}P{0.5874617737003058\textwidth}}
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Year 2015\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Volume XV Issue 1 Version I\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep D D D D ) C\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep (\\
SN\tabcellsep AGE\tabcellsep SEX\tabcellsep P-ANCA\tabcellsep C-ANCA\tabcellsep HISTOLOGICAL DIAGNOSIS\\
1\tabcellsep 19\tabcellsep M\tabcellsep +\tabcellsep \textunderscore \tabcellsep Crescentic Necrotizing Glomerulonephritis\\
2\tabcellsep 25\tabcellsep M\tabcellsep +\tabcellsep \textunderscore \tabcellsep Crescentic Glomerulonephritis\\
3\tabcellsep 22\tabcellsep F\tabcellsep +\tabcellsep \textunderscore \tabcellsep End Stage Renal Disease (ESRD)\\
4\tabcellsep 35\tabcellsep F\tabcellsep +\tabcellsep \textunderscore \tabcellsep Necrotizing Focal And Segmental\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Glomerulonephritis\\
5\tabcellsep 43\tabcellsep M\tabcellsep +\tabcellsep \textunderscore \tabcellsep Crescentic Necrotizing Glomerulonephritis\\
6\tabcellsep 40\tabcellsep F\tabcellsep +\tabcellsep \textunderscore \tabcellsep Necrotizing Focal proliferative Glomerulonephritis\\
8\tabcellsep 10\tabcellsep M\tabcellsep +\tabcellsep +\tabcellsep Focal Necrotizing Glomerulonephritis\\
9\tabcellsep 22\tabcellsep F\tabcellsep \textunderscore \tabcellsep +\tabcellsep Necrotizing Focal proliferative glomerulonephritis\\
10\tabcellsep 70\tabcellsep M\tabcellsep +\tabcellsep +\tabcellsep Diffuse Proliferative And Sclerosing\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Glomerulonephritis (ESRD)\\
11\tabcellsep 45\tabcellsep F\tabcellsep +\tabcellsep \textunderscore \tabcellsep End Stage Renal Disease (ESRD)\\
12\tabcellsep 42\tabcellsep M\tabcellsep \tabcellsep \tabcellsep Diffuse global and Segmental\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Mesangioproliferative glomerulonephritis\\
13\tabcellsep 45\tabcellsep F\tabcellsep +\tabcellsep +\tabcellsep Diffuse Global Glomerular Sclerosis with\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Advanced Diabetic Glomerulopathy (ESRD)\\
14\tabcellsep 21\tabcellsep M\tabcellsep +\tabcellsep -\tabcellsep Crescentic Glomerulonephritis\\
15\tabcellsep 29\tabcellsep M\tabcellsep -\tabcellsep +\tabcellsep Membranous with foci of fibrinoid change\\
\multicolumn{3}{l}{b) Clinico-pathological correlation}\tabcellsep \tabcellsep \tabcellsep symptomswere recorded and later on tabulated\\
\multicolumn{5}{l}{A major part of present study dealt with correlation of clinical presentation according to the histopathological diagnosis. All the signs and}\tabcellsep according to histopathological diagnosis in 114 cases with detailed patient history and physical examination. (Table-4 and 5)\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep © 2015 Global Journals Inc. (US)\end{longtable} \par
 
\caption{\label{tab_2}Table 3 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4} \par 
\begin{longtable}{}
\end{longtable} \par
  {\small\itshape [Note: RCN= Renal cortical necrosis; MPGN= Membranoproliferative glomerulonephritis; DPGN= Diffuse proliferative glomerulonephritis, MEM= Membranous; ESRD= End stage renal disease; MCD= Minimal change disease; DN= Diabetic nephropathy; LN= lupus nephritis; CGN= Crescentic glomerulonephritis; FSGS= Focal segmental glomerulosclerosis; FOS= Focal segmental/proliferative glomerulonephritis; FON= Focal necrotizing glomerulonephritis; MEGN= Mesangioproliferative glomerulonephritis.]} 
\caption{\label{tab_3}Table 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.09962057335581787\textwidth}P{0.05088532883642496\textwidth}P{0.022217537942664418\textwidth}P{0.08313659359190556\textwidth}P{0.02508431703204047\textwidth}P{0.0480185497470489\textwidth}P{0.024367622259696457\textwidth}P{0.030817875210792583\textwidth}P{0.024367622259696457\textwidth}P{0.04515177065767285\textwidth}P{0.025801011804384485\textwidth}P{0.03511804384485666\textwidth}P{0.004300168634064081\textwidth}P{0.02293423271500843\textwidth}P{0.04658516020236088\textwidth}P{0.005016863406408094\textwidth}P{0.025801011804384485\textwidth}P{0.03655143338954469\textwidth}P{0.01863406408094435\textwidth}P{0.025801011804384485\textwidth}P{0.009317032040472175\textwidth}P{0.0057335581787521074\textwidth}P{0.022217537942664418\textwidth}P{0.05088532883642496\textwidth}P{0.03655143338954469\textwidth}P{0.022217537942664418\textwidth}P{0.0028667790893760537\textwidth}}
\multicolumn{24}{l}{Clinical Characteristics and Histopathological Findings in Renal Parenchymal Disease Patients:our}\\
\tabcellsep \tabcellsep \tabcellsep \multicolumn{21}{l}{Single Centre Experience from Northern Plains of India}\\
MEGN\tabcellsep (n=11)\tabcellsep 06\tabcellsep (54.5)\tabcellsep 04\tabcellsep (36.6)\tabcellsep 04\tabcellsep (36.6)\tabcellsep 02\tabcellsep (18.1)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep 05\tabcellsep (45.5)\tabcellsep \tabcellsep -\tabcellsep \tabcellsep -\tabcellsep \tabcellsep \tabcellsep \tabcellsep -\tabcellsep 126/\tabcellsep 86\\
FON\tabcellsep (n=1)\tabcellsep 01\tabcellsep (100)\tabcellsep 01\tabcellsep (100)\tabcellsep 01\tabcellsep (100)\tabcellsep 01\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep -\tabcellsep \tabcellsep \tabcellsep -\tabcellsep \tabcellsep -\tabcellsep \tabcellsep \tabcellsep \tabcellsep -\tabcellsep 210/\tabcellsep 168\\
FOS\tabcellsep (n=10)\tabcellsep 06\tabcellsep (60)\tabcellsep 07\tabcellsep (70)\tabcellsep 04\tabcellsep (40)\tabcellsep 07\tabcellsep (70)\tabcellsep 03\tabcellsep (30)\tabcellsep \tabcellsep 09\tabcellsep (90)\tabcellsep \tabcellsep 01\tabcellsep (10)\tabcellsep 02\tabcellsep (20)\tabcellsep \tabcellsep \tabcellsep 01\tabcellsep (10)\tabcellsep 146/\tabcellsep 96\\
FSGS\tabcellsep (n=10)\tabcellsep 04\tabcellsep (40)\tabcellsep 05\tabcellsep (50)\tabcellsep 02\tabcellsep (20)\tabcellsep 06\tabcellsep (60)\tabcellsep 03\tabcellsep (30)\tabcellsep \tabcellsep 05\tabcellsep (50)\tabcellsep \tabcellsep 01\tabcellsep (10)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep \tabcellsep -\tabcellsep 142/\tabcellsep 96\\
CGN\tabcellsep (n=5)\tabcellsep 04\tabcellsep (80)\tabcellsep 05\tabcellsep (100)\tabcellsep 05\tabcellsep (100)\tabcellsep 05\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep -\tabcellsep \tabcellsep \tabcellsep 03\tabcellsep (60)\tabcellsep 03\tabcellsep (60)\tabcellsep \tabcellsep \tabcellsep 01\tabcellsep (20)\tabcellsep 160/\tabcellsep 100\\
LN\tabcellsep (n=8)\tabcellsep 08\tabcellsep (100)\tabcellsep 06\tabcellsep (75)\tabcellsep 06\tabcellsep (75)\tabcellsep 04\tabcellsep (50)\tabcellsep 03\tabcellsep (37.5)\tabcellsep \tabcellsep 08\tabcellsep (100)\tabcellsep \tabcellsep 03\tabcellsep (37.5)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep \tabcellsep 01\tabcellsep (12.5)\tabcellsep 160/\tabcellsep 100\\
DN\tabcellsep (n=7)\tabcellsep 04\tabcellsep (57.1)\tabcellsep 07\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep 07\tabcellsep (100)\tabcellsep 05\tabcellsep (71.4)\tabcellsep \tabcellsep 06\tabcellsep (85.7)\tabcellsep \tabcellsep 04\tabcellsep (57.1)\tabcellsep 01\tabcellsep (14.2)\tabcellsep \tabcellsep \tabcellsep 04\tabcellsep (57.1)\tabcellsep 200/\tabcellsep 120\\
MCD\tabcellsep (n=5)\tabcellsep 01\tabcellsep (20)\tabcellsep 05\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep 05\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep 02\tabcellsep (40)\tabcellsep \tabcellsep 01\tabcellsep (20)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep \tabcellsep -\tabcellsep 106/\tabcellsep 90\\
ESRD\tabcellsep (n=21)\tabcellsep 15\tabcellsep (71.4)\tabcellsep 21\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep 21\tabcellsep (100)\tabcellsep 21\tabcellsep (100)\tabcellsep \tabcellsep 21\tabcellsep (100)\tabcellsep \tabcellsep 10\tabcellsep (47.6)\tabcellsep 08\tabcellsep (38)\tabcellsep \tabcellsep \tabcellsep 07\tabcellsep (33.3)\tabcellsep 210/\tabcellsep 150\\
MEM\tabcellsep (n=16)\tabcellsep 02\tabcellsep (12.5)\tabcellsep 16\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep 16\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep 11\tabcellsep (68.7)\tabcellsep \tabcellsep -\tabcellsep \tabcellsep -\tabcellsep \tabcellsep \tabcellsep \tabcellsep -\tabcellsep 124/\tabcellsep 96\\
DPGN\tabcellsep (n=10)\tabcellsep 07\tabcellsep (70)\tabcellsep 07\tabcellsep (70)\tabcellsep 08\tabcellsep (80)\tabcellsep 05\tabcellsep (50)\tabcellsep 04\tabcellsep (40)\tabcellsep \tabcellsep 08\tabcellsep (80)\tabcellsep \tabcellsep 03\tabcellsep (30)\tabcellsep 04\tabcellsep (40)\tabcellsep \tabcellsep \tabcellsep -\tabcellsep 148/\tabcellsep 100\\
MPGN\tabcellsep (n=8)\tabcellsep 04\tabcellsep (50)\tabcellsep 02\tabcellsep (25)\tabcellsep 05\tabcellsep (62.5)\tabcellsep 07\tabcellsep (87.5)\tabcellsep 04\tabcellsep (50)\tabcellsep \tabcellsep 06\tabcellsep (75)\tabcellsep \tabcellsep 04\tabcellsep (50)\tabcellsep -\tabcellsep \tabcellsep \tabcellsep \tabcellsep -\tabcellsep 128/\tabcellsep 96\\
RCN\tabcellsep (n=2)\tabcellsep 01\tabcellsep (50)\tabcellsep 02\tabcellsep (100)\tabcellsep -\tabcellsep \tabcellsep 02\tabcellsep (100)\tabcellsep 02\tabcellsep (100)\tabcellsep \tabcellsep 02\tabcellsep (100)\tabcellsep \tabcellsep 02\tabcellsep (100)\tabcellsep 01\tabcellsep (50)\tabcellsep \tabcellsep \tabcellsep 01\tabcellsep (50)\tabcellsep 110/\tabcellsep 80\\
\tabcellsep \tabcellsep Fever\tabcellsep \tabcellsep Oliguria/\tabcellsep Anuria\tabcellsep Cola coloured\tabcellsep urine\tabcellsep Anasarca\tabcellsep \tabcellsep Persist.nausea,\tabcellsep vomiting >3\tabcellsep months\tabcellsep Anaemia,\tabcellsep weakness and\tabcellsep malaise\tabcellsep Pain abdomen/\tabcellsep lump\tabcellsep Altered\tabcellsep sensorium,\tabcellsep confusion and\tabcellsep seizures\tabcellsep Signs of LVF\tabcellsep B.P (Average)\tabcellsep Small joint\tabcellsep pain, alopecia,\tabcellsep rash\end{longtable} \par
 
\caption{\label{tab_4}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5} \par 
\begin{longtable}{P{0.4696381288614298\textwidth}P{0.02700794351279788\textwidth}P{0.0705207413945278\textwidth}P{0.05551632833186231\textwidth}P{0.022506619593998235\textwidth}P{0.022506619593998235\textwidth}P{0.01875551632833186\textwidth}P{0.02850838481906443\textwidth}P{0.02850838481906443\textwidth}P{0.021006178287731686\textwidth}P{0.016504854368932037\textwidth}P{0.029258605472197705\textwidth}P{0.022506619593998235\textwidth}P{0.017255075022065313\textwidth}}
\tabcellsep \tabcellsep \tabcellsep \multicolumn{6}{l}{Glomerulopathies At The Time Of Biopsy}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Urine\tabcellsep \multicolumn{2}{l}{RCN MPG}\tabcellsep DPG\tabcellsep \multicolumn{2}{l}{MEM ESR}\tabcellsep MC\tabcellsep DN\tabcellsep \multicolumn{4}{l}{LN CGN FSGS FO}\tabcellsep \multicolumn{2}{l}{FON ME}\\
Examination\tabcellsep \tabcellsep N\tabcellsep N\tabcellsep \tabcellsep D\tabcellsep D\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep S\tabcellsep \tabcellsep GN\\
CHEMICAL\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
EXAMINATION\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Protein\tabcellsep 2+\tabcellsep 2+\tabcellsep 1+\tabcellsep 3+\tabcellsep 3+\tabcellsep 4+\tabcellsep 1+\tabcellsep 2+\tabcellsep 1+\tabcellsep 3+\tabcellsep 1+\tabcellsep 1+\tabcellsep 2+\\
Sugar\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep 1+\tabcellsep 1+\tabcellsep -\tabcellsep 3+\tabcellsep 1+\tabcellsep 1+\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\\
MICROSCOPIC\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
EXAMINATION\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Pus cells/hpf\tabcellsep 0-3\tabcellsep 0-4\tabcellsep 5-10\tabcellsep 0-5\tabcellsep 20-30\tabcellsep 0-5\tabcellsep 20-\tabcellsep 5-8\tabcellsep 5-10\tabcellsep 1-5\tabcellsep 1-5\tabcellsep 1-2\tabcellsep 1-2\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 30\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
RBC's /hpf\tabcellsep 40-\tabcellsep 5-10\tabcellsep 20-50\tabcellsep 0-3\tabcellsep 5-10\tabcellsep 0-2\tabcellsep 0-3\tabcellsep 8-10\tabcellsep 20-\tabcellsep 2-4\tabcellsep 8-10\tabcellsep 20-\tabcellsep 5-8\\
\tabcellsep 60\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 30\tabcellsep \tabcellsep \tabcellsep 30\tabcellsep \\
Granular\tabcellsep 1-2\tabcellsep 1-2\tabcellsep 5-9\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep 2-5\tabcellsep 2-3\tabcellsep -\tabcellsep 1-2\tabcellsep 1-2\tabcellsep 2-4\\
casts/lpf\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Hyaline\tabcellsep 5-9\tabcellsep 1-2\tabcellsep 1-2\tabcellsep 2-3\tabcellsep 5-8\tabcellsep 1-2\tabcellsep 1-2\tabcellsep 2-3\tabcellsep 3-5\tabcellsep 2-4\tabcellsep 1-4\tabcellsep 2-5\tabcellsep 2-3\\
casts/lpf\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
RBC casts/lpf\tabcellsep 5-9\tabcellsep 1-2\tabcellsep 10-20\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep 2-3\tabcellsep 8-10\tabcellsep -\tabcellsep 3-6\tabcellsep 5-8\tabcellsep -\\
Broad waxy\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep 5-9\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep -\tabcellsep <1\\
casts/lpf\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
BIOCHEMICAL\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\multicolumn{2}{l}{INVESTIGATIONS}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Serum Urea\tabcellsep 168.9\tabcellsep 59.9\tabcellsep 122.6\tabcellsep 34.8\tabcellsep 210.8\tabcellsep 23.0\tabcellsep \multicolumn{3}{l}{77.7 78.9 198.9}\tabcellsep 39.9\tabcellsep \multicolumn{3}{l}{67.8 112.0 80.0}\\
(mg/dl)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Serum\tabcellsep 5.1\tabcellsep 1.2\tabcellsep 3.1\tabcellsep 0.8\tabcellsep 6.9\tabcellsep 0.5\tabcellsep 2.3\tabcellsep 1.9\tabcellsep 7.10\tabcellsep 1.2\tabcellsep 1.9\tabcellsep 4.7\tabcellsep 1.8\\
Creatinine\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
(mg/dl)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\multicolumn{14}{l}{RCN= Renal cortical necrosis; MPGN= Membranoproliferative glomerulonephritis; DPGN= Diffuse proliferative}\\
\multicolumn{14}{l}{glomerulonephritis, MEM= Membranous; ESRD= End stage renal disease; MCD= Minimal change disease; DN=}\\
\multicolumn{14}{l}{Diabetic nephropathy; LN= lupus nephritis; CGN= Crescentic glomerulonephritis; FSGS= Focal segmental}\\
\multicolumn{13}{l}{glomerulosclerosis; FOS= Focal segmental/proliferative glomerulonephritis; FON= Focal necrotizing}\tabcellsep \\
\tabcellsep \tabcellsep \multicolumn{9}{l}{glomerulonephritis; MEGN= mesangioproliferative glomerulonephritis}\tabcellsep \tabcellsep \tabcellsep \\
\multicolumn{2}{l}{IV.}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_5}Table 5 :}\end{figure}
 			\footnote{© 2015 Global Journals Inc. (US)} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[Chandrika BK Non neoplastic renal diseases in Kerala, India-analysis of 1592 cases; a two year retrospective study Ind J Pathol Micro ()]{b3}\label{b3} 	 		‘Chandrika BK Non neoplastic renal diseases in Kerala, India-analysis of 1592 cases; a two year retrospective study’.  	 	 		\textit{Ind J Pathol Micro}  		2007. 50  (2)  p. .  	 
\bibitem[Narsimhan et al. ()]{b2}\label{b2} 	 		‘Characterization of kidney lesions in Indian adults: towards a renal biopsy registry’.  		 			B Narsimhan 		,  		 			B Chacko 		,  		 			G T John 		.  	 	 		\textit{J Nephrol}  		2006. 19  (2)  p. .  	 
\bibitem[Chen et al. ()]{b8}\label{b8} 	 		‘Pathological demography of native patients in a nephrology center in China’.  		 			H Chen 		,  		 			Z Tang 		,  		 			C Zeng 		.  	 	 		\textit{Chin Med J}  		2003. 116 p. 81.  	 
\bibitem[Minz et al. ()]{b9}\label{b9} 	 		‘Renal histology in pauci-immune rapidly progressive glomerulonephritis: 8 year retrospective study’.  		 			R V Minz 		,  		 			S Chhabra 		,  		 			K Joshi 		,  		 			Rani L Sharma 		,  		 			N Sakhuja 		,  		 			V Duggal 		,  		 			R Pasricha 		,  		 			N 		.  	 	 		\textit{Ind J Pathol Microbiol}  		2012. 55  (1)  p. .  	 
\bibitem[Al-Khader et al. ()]{b6}\label{b6} 	 		‘Renal histology in Saudi population with overt nephrotic syndrome’.  		 			A Al-Khader 		,  		 			Al Sulaiman 		,  		 			M Dhar 		,  		 			JM 		.  	 	 		\textit{Ann Saudi Med}  		1990. 5 p. 581.  	 
\bibitem[Kumar Abbas ()]{b0}\label{b0} 	 	 	 		\textit{Robbins and Cotran pathologic basis of disease. 7 th Ed. Philadelphia: WB Saunders},  				 			V Kumar,  			A K Abbas 		 (ed.)  		2004. 2007. p. 977.  	 	 (Reprint) 
\bibitem[Balakrishnan et al. ()]{b1}\label{b1} 	 		‘Spectrum of biopsy proven renal disease and changing trends at a tropical tertiary care centre1990 -2001’.  		 			N Balakrishnan 		,  		 			G T John 		,  		 			A Korula 		.  	 	 		\textit{Indian J Nephrol}  		2003. 13 p. .  	 
\bibitem[Mannan et al. ()]{b4}\label{b4} 	 		‘The Pattern of glomerulonephritis in north Indian gangetic plain-a 13 year epidemiological study’.  		 			R Mannan 		,  		 			T S Bhasin 		,  		 			V Misra 		,  		 			P A Singh 		,  		 			M Manjari 		.  	 	 		\textit{J Clin Diagn Res}  		2012. 6  (5)  p. .  	 
\bibitem[Korbet et al. ()]{b10}\label{b10} 	 		‘The racial prevalence of glomerular lesions in nephrotic adults’.  		 			S M Korbet 		,  		 			R M Genchi 		,  		 			R Z Borok 		,  		 			M M Schwartz 		.  	 	 		\textit{Am J Kidney Dis}  		1996. 27 p. .  	 
\bibitem[Huraib et al. ()]{b7}\label{b7} 	 		‘The spectrum of renal disease found by kidney biopsies at King Khalid University Hospital’.  		 			S O Huraib 		,  		 			H Abu-Aisha 		,  		 			A Mitwalli 		.  	 	 		\textit{Saudi Kidney Dis Transplant Bull}  		1990. 1 p. .  	 
\bibitem[Agarwal and Dash ()]{b5}\label{b5} 	 		‘The spectrum of renal diseases in Indian adults’.  		 			S K Agarwal 		,  		 			S C Dash 		.  	 	 		\textit{J Assoc Physicians India}  		2000. 48 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
